Monopar Therapeutics MNPR Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $52.54M-15.0% | $61.83M-51.6% | $127.68M+223% | $39.5M-0.5% | $39.71M-13.3% | ||
| $52.37M-14.0% | $60.88M-52.3% | $127.5M+224% | $39.33M-0.5% | $39.51M-13.2% | ||
| $137.74M-1.9% | $140.46M-2.5% | $144.09M+168% | $53.75M-2.4% | $55.08M-8.6% | ||
| $239.88K-5.9% | $254.92K+139% | $106.67K-9.7% | $118.17K+1,198% | $9.1K— | ||
| $84.95M+8.1% | $78.57M+391% | $16M+16.4% | $13.75M-7.4% | $14.84M+3.1% | ||
| $137.98M-1.9% | $140.72M-2.4% | $144.2M+168% | $53.87M-2.2% | $55.09M-8.6% | ||
| $2.46M-10.1% | $2.74M+6.5% | $2.57M+62.2% | $1.58M+6.1% | $1.49M-33.8% | ||
| $98.86K+9.2% | $90.57K+189% | $31.36K-6.0% | $33.37K+304% | $8.25K— | ||
| $2.46M-10.1% | $2.74M+6.5% | $2.57M+62.2% | $1.58M— | —— | ||
| $131.57K-15.1% | $154.92K+119% | $70.88K-11.8% | $80.37K— | $0— | ||
| $230.43K-6.1% | $245.49K+140% | $102.24K-10.1% | $113.74K+1,278% | $8.25K— | ||
| $2.59M-10.4% | $2.89M+9.5% | $2.64M+58.6% | $1.66M+11.5% | $1.49M-71.6% | ||
| $6.7K+0.1% | $6.69K+0.4% | $6.66K+8.7% | $6.13K+0.2% | $6.12K+0.2% | ||
| $228.69M+0.7% | $227.2M+0.6% | $225.85M+69.8% | $132.99M+0.7% | $132.03M+0.9% | ||
| -$93.4M-4.3% | -$89.51M-6.2% | -$84.31M-4.3% | -$80.87M-3.1% | -$78.42M-3.5% | ||
| $98.52K-25.0% | $131.39K+1,023% | $11.7K-84.9% | $77.58K+456% | -$21.78K-161% | ||
| $135.39M-1.8% | $137.83M-2.6% | $141.56M+171% | $52.2M-2.6% | $53.59M-2.6% | ||
| $137.98M-1.9% | $140.72M-2.4% | $144.2M+168% | $53.87M-2.2% | $55.09M-8.6% | ||
| —— | —— | —— | —— | —— | ||
| $52.37M-14.0% | $60.88M-52.3% | $127.5M+224% | $39.33M-0.5% | $39.51M-13.2% | ||
| $250.9K+294% | $63.75K-84.6% | $414.83K-16.6% | $497.29K-5.0% | $523.56K+564% | ||
| $239.88K-5.9% | $254.92K+139% | $106.67K-9.7% | $118.17K+1,198% | $9.1K— | ||
| $84.95M+8.1% | $78.57M+391% | $16M+16.4% | $13.75M-7.4% | $14.84M+3.1% | ||
| $239.88K-5.9% | $254.92K+139% | $106.67K-9.7% | $118.17K+1,198% | $9.1K— | ||
| $239.88K-5.9% | $254.92K+139% | $106.67K-9.7% | $118.17K+1,198% | $9.1K— | ||
| $2.46M-10.1% | $2.74M+6.5% | $2.57M+62.2% | $1.58M+6.1% | $1.49M-33.8% | ||
| $230.43K-6.1% | $245.49K+140% | $102.24K-10.1% | $113.74K+1,278% | $8.25K— | ||
| $228.69M+0.7% | $227.2M+0.6% | $225.85M+69.8% | $132.99M+0.7% | $132.03M+0.9% | ||
| $6.7K+0.1% | $6.69K+0.4% | $6.66K+8.7% | $6.13K+0.2% | $6.12K+0.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Monopar Therapeutics's total assets?
- Monopar Therapeutics (MNPR) holds $138.0M in total assets, up 150.5% year over year.
- How much debt does Monopar Therapeutics have?
- Monopar Therapeutics carries $230.4K in total debt against $135.4M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Monopar Therapeutics have?
- Monopar Therapeutics holds $52.5M in cash and equivalents.
- Can Monopar Therapeutics cover its short-term obligations?
- Its current ratio is 56.04 — current assets exceed current liabilities.
- Where does Monopar Therapeutics's balance sheet data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.